180 related articles for article (PubMed ID: 35086853)
1. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
Lazzerini G; Lavey SC; Fox BC; Munson E
Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
[No Abstract] [Full Text] [Related]
2.
Schulte RH; Munson E
Clin Med Res; 2019 Dec; 17(3-4):72-81. PubMed ID: 31582419
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology: Introduction to the Program and Summary of 2016 Geographic Variation.
Munson E; Hueppchen E; Zeman H
WMJ; 2018 Aug; 117(3):116-121. PubMed ID: 30193020
[TBL] [Abstract][Full Text] [Related]
4. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
Humphries RM; Hindler JA; Shaffer K; Campeau SA
J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567744
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): 2018-2019 Report on
Reynoso A; Munson E
Clin Med Res; 2021 Sep; 19(3):123-131. PubMed ID: 34531269
[No Abstract] [Full Text] [Related]
8. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
Van TT; Minejima E; Chiu CA; Butler-Wu SM
J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
[TBL] [Abstract][Full Text] [Related]
11. Changes in
Munson E; Lavey SC; Lasure MR; Fox BC
Clin Med Res; 2022 Dec; 20(4):185-194. PubMed ID: 36581396
[No Abstract] [Full Text] [Related]
12. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
Kassim A; Omuse G; Premji Z; Revathi G
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
[TBL] [Abstract][Full Text] [Related]
14. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
Süzük S; Kaşkatepe B; Avcıküçük H; Aksaray S; Başustaoğlu A
Mikrobiyol Bul; 2015 Oct; 49(4):494-501. PubMed ID: 26649407
[TBL] [Abstract][Full Text] [Related]
15. Delafloxacin
Pfaller MA; Flamm RK; McCurdy SP; Pillar CM; Shortridge D; Jones RN
J Clin Microbiol; 2018 Aug; 56(8):. PubMed ID: 29848564
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
17.
McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.
Lautenbach E; Metlay JP; Mao X; Han X; Fishman NO; Bilker WB; Tolomeo P; Wheeler M; Nachamkin I
Clin Infect Dis; 2010 Aug; 51(3):280-5. PubMed ID: 20597679
[TBL] [Abstract][Full Text] [Related]
20. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
